SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,811.032761 with 281,866,747.320393 in circulation. The last known price of OFFICIAL TRUMP is 1.57555883 USD and is down -1.93 over the last 24 hours. It is currently trading on 744 active market(s) with $126,884,732.61 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

The TRUMP meme coin is drawing attention amid discussion of its steep decline from launch highs and allegations that Trump-linked insiders profited while retail holders lost money. Many traders call it a scam and expect further downside, while some remain bullish on accumulation or a possible short squeeze.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

OXYs breakout to a six-month high amid strength in oil stocks is drawing attention, with bullish call-option activity adding to the momentum. Traders are watching for follow-through, while others question why the shares have not tracked crude prices more closely and point to resistance ahead.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotify shares are rallying after its latest quarterly report, as subscriber growth, improving gross margin and a stronger profit outlook outweighed modest revenue and EPS misses. Traders are debating the disconnect between the headline misses and the positive market reaction, with many pointing to forward guidance as the key driver.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owls Q3 results and upbeat earnings-call outlook are driving attention, with traders highlighting fee and AUM growth, dividend coverage, and unearned-fee backlog as reasons for optimism. Some remain cautious about private-credit redemptions and whether fee growth is durable, while bullish traders see the results as a counterpoint to lingering sector concerns.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstones reported expectation that Anthropic could receive a speculative-grade credit rating, reversing its earlier outlook, has drawn attention amid scrutiny of AI financing risk. Traders debate whether the report intensified selling, while call-heavy options activity is viewed by some as positioning rather than a clear bullish bet.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons Q3 earnings beat, driven in part by strong refining margins and record U.S. refinery throughput, is the main catalyst. Traders are reacting bullishly to the results and call-heavy options activity, while some question whether the refining boost will last.

Pyth Network (PYTH) is a cryptocurrency launched in 2021and operates on the Solana platform. Pyth Network has a current supply of 9,999,981,857.422035 with 7,874,958,862.767691 in circulation. The last known price of Pyth Network is 0.06608465 USD and is up 1.61 over the last 24 hours. It is currently trading on 450 active market(s) with $21,484,088.50 traded over the last 24 hours. More information can be found at https://pyth.network/.

Pyth Network

Pyths Nasdaq data-distribution and broader real-world-asset push are fueling bullish discussion, alongside the DAOs policy directing product revenue toward PYTH reserve accumulation. Traders see these developments as strengthening the tokens demand story, while others point to weak price action and potential token-unlock selling pressure.

VXX tracks an index with exposure to futures contracts on the CBOE Volatility Index with average one-month maturity. Exposure resets daily.

Barclays Bank PLC - iPathÂ® Series B S&P 500Â® VIX Short-Term FuturesTM ETN

iPath S&P 500 VIX Short-Term Futures ETN

A rebound in volatility has put VXX in focus as traders weigh hedging for a possible market pullback amid broader uncertainty. Some see the move as the start of a sustained volatility breakout, while others expect a short-lived pop and point to VXXs futures-related decay as a reason to fade rallies.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

CCXI is drawing attention as the SPAC vehicle for Agility Robotics and its humanoid-robotics business, with traders debating the companys commercial potential and industry momentum against concerns about losses, valuation, dilution, and the loss of SPAC redemption support. The community is split between bullish bets on robotics and cautious reactions to the sharp decline and downside-leaning options activity.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings beat is driving a sharp rally and a new 52-week high, with traders highlighting growth across Dupixent, Eylea HD and Libtayo. The reaction is broadly bullish, though some note that declining legacy Eylea sales and potential profit-taking could temper the momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise

SNY beats Q3 earnings and sales estimates as Dupixent drives growth and the company raises its 2026 outlook for sales and business EPS.

Sanofi Q3 Net Profit, Business Profit Climb; Lifts FY26 Outlook

(RTTNews) - French drug major Sanofi SA (SNY, SNYNF, SAN.PA) reported Friday higher net profit and business net income in its third quarter, with strong sales growth. Further, the firm upgraded its fiscal 2026 outlook...

ExxonMobil, AbbVie On Deck Friday As Energy, Drug Growth Face Test

ExxonMobil headlines Friday's reports, with investors watching whether strong energy production can sustain a sharp earnings recovery. AbbVie, Chevron, AstraZeneca, BP, Sanofi, General Dynamics, Regeneronread more...

How The NYT Hid Big Pharma PR Titan Jack Leslie In Plain Sight

How The NYT Hid Big Pharma PR Titan Jack Leslie In Plain Sight

 Authored by Paul D. Thacker via The DisInformation Chronicle,

New York Times reporter Sheryl Gay Stolberg wrote one of the most hilarious, misleading pieces I've seen in recent months, castigating the NIH for a new vaccine...

GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth

GSK's newer drugs, expanding indications and promising pipeline could drive long-term growth, with sales expected to exceed 40 billion pounds by 2031.

Sanofi Commences Construction Of Insulin Facility In Frankfurt, Germany

(RTTNews) - Monday, Sanofi (SNY) commenced construction of a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany, leveraging advanced digital technologies and artificial intelligence across manufacturing and quality processes...

RXRX Stock Heads For Its Best Day In Over A Year – What’s Driving The Rally Today? 

Equity

Sanofi selected its first drug development candidate under its collaboration with Recursion.

Sanofi Must Set Record Straight on Rival Flu Shot Under EU Antitrust Deal

Sanofi settles EU antitrust probe over rival flu vaccine Fluad, agreeing to binding promotional rules through 2030.read more...

Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?

NKTR advances rezpeg into phase III studies for atopic dermatitis, with additional autoimmune indications offering potential growth amid stiff competition.

Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?

Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales challenges.

$SNY Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $2.01 up 17.54% YoY
• Reported revenue of $17.25B up 11.64% YoY
• Sanofi upgraded FY 2026 guidance: sales are expected to grow by a low-teens percentage at CER, and business EPS at CER is expected to grow by a mid-teens percentage.

Stocktwits

Sanofi-Aventis

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of $2.01 up 17.54% YoY
• Reported revenue of $17.25B up 11.64% YoY
• Sanofi upgraded FY 2026 guidance: sales are expected to grow by a low-teens percentage at CER, and business EPS at CER is expected to grow by a mid-teens percentage.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of $2.01 up 17.54% YoY
• Reported revenue of $17.25B up 11.64% YoY
• Sanofi upgraded FY 2026 guidance: sales are expected to grow by a low-teens percentage at CER, and business EPS at CER is expected to grow by a mid-teens percentage.

Sanofis vaccine sales decreased 6.6% at CER amid influenza phasing and lower Beyfortus US sales; net debt increased, while management identified Dupixent loss of exclusivity as an earnings priority.

Sanofis Dupixent and pharma launches grew, Q3 business EPS and operating income increased, and expanded Regeneron collaboration added four next-generation antibodies alongside positive phase 2 lunsekimig data.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines, vaccines franchises, support, and corporate functions 1973 and is headquartered in Paris, France.

Sanofi - ADR

Bullish Sentiment

<ul class="summary-bullets"><li>Recursion could receive over $300 million in additional milestone payments from the program.</li><li>Sanofi will fund the development of the drug, with Phase 1 clinical trials expected to begin in 2027.</li><li>Recursion priced a $200 million underwritten offering at $3.25 per share.</li></ul>Shares of Recursion Pharmaceuticals (RXRX) surged more than 16% on Thursday after French drugmaker Sanofi (SNY) selected an experimental treatment for inflammatory diseases developed through their multi-program research collaboration.The update comes alongside a $200 million stock offering that Recursion expects will fund operations into 2029.If the current levels hold, <a class="mention" data-mention="$RXRX" data-symbol-id="RXRX" href="https://stocktwits.com/symbol/RXRX" target="_blank">RXRX stock</a> would record its biggest single-day gains in almost a year.&nbsp;<h2 class="st-heading-2">Sanofi Picks First Drug Candidate Under Partnership</h2>Sanofi’s selection triggered a $10 million milestone payment for Recursion. The experimental oral drug targets two biological mechanisms involved in inflammatory diseases. It is designed to target two biological factors involved in inflammatory diseases.Recursion used its AI-enabled drug design platform and small-molecule chemistry capabilities along with Sanofi’s expertise in drug discovery and immunology to develop the drug.Sanofi will fund the development of the drug, with Phase 1 clinical trials expected to begin in 2027.Recursion has now received $144 million in upfront and milestone payments under the partnership. It could earn more than $300 million in additional payments from this program, alongside royalties if the drug is commercially approved.Sanofi and Exscientia signed a drug development partnership in January 2022. Exscientia was subsequently merged with Recursion two years later.The agreement covers up to 15 potential therapies targeting cancer and immune-related diseases, with Recursion eligible for about $5.2 billion in milestone payments if all programs meet their targets.<h2 class="st-heading-2">Recursion’s $200M Fundraising</h2>Recursion also priced a public offering of 61.5 million shares at $3.25 each, aiming to raise about $200 million before expenses. This was a 13% discount to the stock’s closing price on Wednesday.Investors participating in the offering include ARK Invest, Janus Henderson Investors, Invus and Driehaus Capital Management.Recursion had around $561 million in preliminary cash, cash equivalents and restricted cash at the end of September. September-end. Its new equity offering is expected to extend its projected cash runway into 2029.<h2 class="st-heading-2">Retail’s Take On RXRX</h2>Retail sentiment on Stocktwits surrounding RXRX remained ‘bearish’ over the past 24 hours despite the rally.The stock is up about 2% so far this year.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/spacex-united-airlines-after-aal-rollout-starlink/cZxWys7RBrb">&nbsp;</a><a href="https://stocktwits.com/news-articles/markets/equity/fmc-stock-crashes-on-massive-earnings-downgrade-citi-expects-modest-negative-reaction-for-peer-corteva/cZxhGzwRBr3">FMC Stock Crashes 33% On Massive Earnings Downgrade – Citi expects ‘Modest Negative Reaction’ For Peer Corteva</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Recursion is an American biotechnology company that combines machine learning, automation, and experimental biology. (Photo illustration by Cheng Xin/Getty Images)

Recursion Pharmaceuticals Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$44.34
Prev Close	$43.13
Open	$44.82
Dividend Yield	3.64%
50-Day Moving Average	$42.21
Beta	0.27
Avg. Volume	2.57M
PE Ratio	22.74

52-Week High	$52.68
52-Week Low	$39.07
Market Capitalization	$105.68B
EPS (Annual)	$2.41
Price to Book	1.36
Revenue Per Employee	$643,658.13

Feed

News

Sentiment

Earnings

Fundamentals

Info

SNY Fundamentals